Nuvalent, Inc., a biopharmaceutical company specialising in targeted cancer therapies, has seen its stock price skyrocket following the release of compelling data from two clinical trials at the European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona. The company’s shares surged by more than 22%, driven by positive data on its novel cancer drugs, […]
Incyte has announced new early-stage clinical data for INCB123667, a highly selective and potential first-in-class CDK2 inhibitor, showing promising results in patients with advanced solid tumors, particularly ovarian cancer. The data were presented during the European Society of Medical Oncology (ESMO) Congress 2024 and later updated during an Incyte investor event, emphasising the potential of […]
Agenus Inc. (Nasdaq: AGEN), a pioneer in the development of immunological agents for cancer treatment, has recently unveiled promising results from an investigator-sponsored trial (IST) of its novel therapies, botensilimab and balstilimab (BOT/BAL), for treating colon cancer. These findings were presented at the 2024 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress in Munich, […]